Lancet Diabetes Endocrinol 6(8):605617 Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB et al (2018b) Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
GLP-1 drugs show promise for weight management Across the reviews, tirzepatide, semaglutide, and liraglutide each led to significant weight loss compared to placebo after one to two years, with these effects likely to be sustained while treatment continues
Its not about knowing what to eat and not eat, or how to exerciseI have all the knowledge, says the self-described health nut who ultimately turned to semaglutide to get back to her pre-menopausal weight
Depending on the drug, it may also lower cardiovascular risk or the likelihood of kidney complications in those with type 2 diabetes, ease heart failure symptoms, reduce liver fat, improve metabolic dysfunction, and lessen the severity of sleep apnea
Age and hormonal factors Metabolic rate declines naturally with age, and hormonal changes during perimenopause, menopause, and andropause compound the challenge